Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune MicroenvironmentNicholas Denton, Timothy P. Cripe, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2018Cited by 56
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L. Leddon, Timothy P. Cripe, Francesca Jung et al.|Molecular Therapy — Oncolytics|2014Cited by 44
VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid CellsMark A. Currier, Timothy P. Cripe, Francis K. Eshun et al.|Molecular Therapy|2013Cited by 40
Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian CancerChelsea Bolyard, Balveen Kaur, Ji Young Yoo et al.|Clinical Cancer Research|2014Cited by 32
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P. Cripe, Gregory K. Friedman, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2015Cited by 22